Management of borderline ovarian tumors.

Tîrnovanu Mihaela-Camelia, Amancei Simona, Dumitrescu A, Onofriescu M, Dumitraşcu Irina

University of Medicine and Pharmacy, Grigore T. Popa - lasi Faculty of Medicine.

Rev Med Chir Soc Med Nat Iasi. 2012 Oct-Dec;116(4):1069-75.

UNLABELLED

Borderline ovarian tumors are an intermediate stage between benign cystadenomas and adenocarcinomas.

AIM

The paper evaluates the management of borderline ovarian tumors (BOTs) in the patients admitted and treated in our clinic in the interval January 2003 - June 2011.

MATERIAL AND METHODS

The observation sheets and pathology results of 264 patients with malignant ovarian tumors were analyzed.

RESULTS

Of the 264 malignant ovarian tumors 74 (28.03%) were low malignant potential. Patients with BOT were aged 18-72 years (mean 46 +/- 6.2 years) and those with invasive tumors 14-83 years (mean 53 +/- 9.8 years). 92.18% were in stage 1. Sixty tumors were graded G1. 53.52 % of the tumors were over 10 cm (maximum 30 cm) in size. The histological types were: serous - 35 cases, mucinous - 19 cases, mixed (serous and mucinous) - 8 cases, and endometrioid - 2 cases. Fifteen patients presented intraepithelial carcinoma and 11 noninvasive implants into the peritoneal cavity. Five women had recurrences.

CONCLUSIONS

Ovarian borderline tumors with histological characteristics of carcinoma, but with good behavior are now with better defined histological features. The biggest challenge in the management of women with these tumors is to identify the subset that will behave in a malignant fashion and to develop effective treatment for them.